11/6
08:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
10/25
01:32 pm
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/25
01:32 pm
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/21
08:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $20.00 price target on the stock.
Medium
Report
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $20.00 price target on the stock.
10/8
08:43 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/8
08:43 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/8
08:39 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $29.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $29.00 price target on the stock.
10/7
10:14 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/3
11:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/3
11:01 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/3
10:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
10/3
10:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
10/3
09:42 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS
10/3
09:42 am
rcus
Rating for RCUS
Low
Report
Rating for RCUS